Calliditas Therapeutics AB stock is up 7.84% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November. 100% of analysts rate it a buy.
Calliditas Therapeutics AB (publ) focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy.